AIA Group Ltd Makes New Investment in Maximus, Inc. $MMS

AIA Group Ltd purchased a new stake in Maximus, Inc. (NYSE:MMS) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 13,177 shares of the health services provider’s stock, valued at approximately $1,204,000.

Several other institutional investors and hedge funds also recently made changes to their positions in MMS. Magnetar Financial LLC boosted its holdings in shares of Maximus by 123.5% during the 2nd quarter. Magnetar Financial LLC now owns 12,774 shares of the health services provider’s stock worth $897,000 after buying an additional 7,059 shares in the last quarter. Deprince Race & Zollo Inc. increased its stake in shares of Maximus by 147.1% in the 3rd quarter. Deprince Race & Zollo Inc. now owns 243,695 shares of the health services provider’s stock valued at $22,266,000 after acquiring an additional 145,062 shares in the last quarter. Boston Partners lifted its position in shares of Maximus by 113.6% during the 2nd quarter. Boston Partners now owns 657,247 shares of the health services provider’s stock valued at $46,435,000 after acquiring an additional 349,529 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Maximus by 19.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 200,331 shares of the health services provider’s stock valued at $18,304,000 after acquiring an additional 33,136 shares during the period. Finally, Creative Planning boosted its stake in Maximus by 77.1% during the second quarter. Creative Planning now owns 37,582 shares of the health services provider’s stock worth $2,638,000 after acquiring an additional 16,363 shares in the last quarter. Institutional investors and hedge funds own 97.21% of the company’s stock.

Maximus Trading Down 0.7%

NYSE:MMS opened at $68.23 on Friday. The company has a 50-day moving average price of $82.25 and a 200-day moving average price of $85.08. Maximus, Inc. has a 12 month low of $64.68 and a 12 month high of $100.00. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 0.88. The stock has a market cap of $3.72 billion, a price-to-earnings ratio of 10.39 and a beta of 0.59.

Maximus (NYSE:MMS) last announced its quarterly earnings results on Thursday, February 5th. The health services provider reported $1.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.84 by $0.01. Maximus had a net margin of 6.92% and a return on equity of 25.30%. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.37 billion. During the same quarter in the previous year, the company earned $1.61 earnings per share. Maximus’s quarterly revenue was down 4.1% on a year-over-year basis. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. Equities analysts predict that Maximus, Inc. will post 6.15 EPS for the current year.

Maximus Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were paid a $0.33 dividend. This represents a $1.32 annualized dividend and a dividend yield of 1.9%. The ex-dividend date was Friday, February 13th. This is a positive change from Maximus’s previous quarterly dividend of $0.30. Maximus’s dividend payout ratio (DPR) is 20.09%.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Wall Street Zen cut shares of Maximus from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Weiss Ratings downgraded Maximus from a “buy (b)” rating to a “hold (c+)” rating in a research note on Tuesday, February 24th. Finally, Zacks Research raised Maximus from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 30th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Maximus currently has a consensus rating of “Buy”.

Insider Buying and Selling

In other Maximus news, CFO David Mutryn purchased 1,000 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was bought at an average cost of $75.62 per share, with a total value of $75,620.00. Following the transaction, the chief financial officer directly owned 40,037 shares in the company, valued at approximately $3,027,597.94. The trade was a 2.56% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jan Madsen sold 742 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $72.25, for a total value of $53,609.50. Following the completion of the sale, the director owned 20,795 shares in the company, valued at $1,502,438.75. The trade was a 3.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.80% of the stock is owned by company insiders.

Maximus Company Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.